Compare
Nu-Med Plus, Inc. vs Odyssey Health, Inc. vs Global Innovative Platforms Inc. vs Sigyn Therapeutics, Inc.
| Latest fiscal year | Nu-Med Plus, Inc. NUMD | Odyssey Health, Inc. ODYY | Global Innovative Platforms Inc. GIPL | Sigyn Therapeutics, Inc. SIGYLast annual report: year ended 2024-12-31 |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-07-31 | 2025-09-30 | 2024-12-31 |
| Revenue | n/a | n/a | $0 | n/a |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$56.2K | -$1.74M | -$718.3K | -$3.34M |
| EPS (Diluted) | $0.00 | -$0.02 | -$0.02 | -$2.51 |
| Operating cash flow | -$48.0K | -$347.4K | -$560.7K | -$872.4K |
| Free cash flow | n/a | n/a | n/a | n/a |
| Cash & equivalents | n/a | n/a | n/a | $12.1K |
| Total assets | $7.9K | $49.7K | $199.3K | $213.7K |
| Total liabilities | $279.2K | n/a | $11.6K | $4.67M |
| Shareholders' equity | -$271.3K | -$6.95M | $187.7K | -$4.46M |
| Return on year-end equity | n/a | n/a | -382.7% | n/a |
| Shares outstanding | 83.55M | 96.71M | 44.48M | 1.61M |
Revenue, most recent five fiscal years
| Fiscal year | Nu-Med Plus, Inc. | Odyssey Health, Inc. | Global Innovative Platforms Inc. | Sigyn Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2020-12-31 | $0 Ended 2020-07-31 | $0 Ended 2025-09-30 | $143.3K Ended 2019-12-31 |
| 1 year earlier | $0 Ended 2019-12-31 | $0 Ended 2019-07-31 | $0 Ended 2024-09-30 | $28.3K Ended 2018-12-31 |
| 2 years earlier | $0 Ended 2018-12-31 | $0 Ended 2018-07-31 | $0 Ended 2023-09-30 | $38.4K Ended 2017-12-31 |
| 3 years earlier | $0 Ended 2017-12-31 | $0 Ended 2017-07-31 | $0 Ended 2022-09-30 | n/a |
| 4 years earlier | $0 Ended 2016-12-31 | $37.5K Ended 2016-07-31 | $0 Ended 2021-09-30 | n/a |